HPLC柱切换法对炔诺酮α，β－聚（3－羟丙基）－DL－天冬酰胺在兔体内释放炔诺酮的测定

以柱切换ＨＰＬＣ（ＣＳＨＰＬＣ）技术，对炔诺酮α，β－聚（３－羟丙基）－ＤＬ天冬酰胺在家兔体内释放液中炔诺酮的血药浓度进行了测定，以自制ＯＤＳ预柱，水为流动相联机净化、富集样品；以Ｓｈｉｍ－ｐａｃｋＣＬＣ－ＯＤＳ为分析柱，甲醇－水（７：３）为流动相。结果表明ＣＳＨＰＬＣ对炔诺酮血药浓度有良好的选择性，回收率为８２．６％（ｎ＝５），日内和日间精密度（ＲＳＤ）分别小于４％和６％。在血清０．２２～１．１０μｇ／ｍ１范围内炔诺酮色谱峰面积与浓度有较好的线性关系（ｎ＝５，ｒ＝０．９９８）．     

兔口服炔诺酮肟和炔诺酮的药代动力学

本文用高效液相色谱分离、液闪测定放射性的方法,测定了兔口服炔诺酮肟(NETO)和炔诺酮(NET)的血浓,并比较了二者的药代动力学参数。结果表明:二者吸收迅速,从血中的消除均呈快慢两个时相。NETO在兔体内一部分迅速转变为NET,另一部分则以原药形式存在,24 h内NETO与其代谢产物NET在血清中的浓度大致各占一半。兔口服NETO与NET后,血浓—时间曲线符合二室模型,NETO的达峰时间比NET短,二者有显著差异(P<0.05),其它动力学参数无明显差异(P>0.05)。     

麦冬类中药组织切片计算机三维重建图鉴

利用计算机技术实现麦冬类中药组织连续切片三维重建与动态显示,为计算机辅助生药学鉴定和教学提供了新的三维图像技术和研究资料。     

精神分裂症患者血浆高香草酸浓度与临床症状、性别和药物治疗的关系

目的：通过分析精神分裂症患者中枢多巴胺代谢产物－血浆高香草酸浓度（ｐＨＶＡ）与临床指征的关系,进一步探讨多巴胺神经递质及其药物治疗在精神分裂症的作用。方法在４６例长期药物治疗、５８例未治疗精神分裂症患者中,采用高液相色谱连接电化学分析仪测定ＰＨＶＡ;测前评定阳性症状量表（ＳＡＰＳ）和阴性症状量表（ＳＡＮＳ）。结果（１）与６２例健康对照组比,治疗组ＰＨ－ＶＡ显著减低,未治疗组显著增高,以阴性症状组为     

Developing best practice for fungal specimen submission - fungal audit of general practice

The objective of this study was to investigate the management of suspected fungal nail infections by general practitioners (GPs) and determine whether guidance is sought when submitting specimens for investigation or treating cases. Questionnaires were sent to all GPs (n = 2420) served by five Health Protection Agency (HPA) collaborating laboratories in the South West of England. A total of 769 GPs responded – topical and oral antifungals were never used by 29% and 16% of GPs respectively. When antifungals were prescribed, topicals were normally given because of the severity of infection (32%); Amorolofine (53%) was the preferred choice. Oral antifungals were most often prescribed after receipt of a laboratory report (77%); Terbinafine was the preferred choice (86%). Seventy percent of GPs would only treat a suspected nail infection with oral antifungals after sending a sample for investigation, yet 27% never waited for a microscopy report before prescribing oral antifungal treatment. GPs routinely send specimens from suspected fungal nail infections for microbiological investigation, yet treatment is often prescribed before a result is received. With clinical signs of fungal infections often non‐specific, GPs should rely on laboratory results before prescribing expensive and lengthy antifungal treatments. Laboratories could further reduce antifungal use by including guidance on microscopy and culture reports.     

Development of health‐related quality of life and symptoms in patients with advanced cancer in Greenland

A prospective national cohort study assessed the development of health‐related quality of life (HRQoL) and symptoms in adult patients undergoing treatment and care for advanced cancer in Greenland. HRQol was examined by EORTC QLQ‐C30 version 3.0 questionnaire monthly for 4 months. Changes over time and between‐group comparisons were examined. Of 58 patients included in the study, 47% completed the questionnaire four times. Functioning was generally high, and improved social functioning was observed after 1 and 2 months. The highest symptom score was for fatigue followed by pain and nausea/vomiting. A high score for financial problems remained unchanged during the entire period. Patients with higher income had reduced pain intensity (p = .03) and diarrhoea (p = .05) than patients with income below the poverty line. After 1 month, reduction in pain intensity was observed for Nuuk citizens compared with non‐Nuuk citizens (p = .05). After 2 months, non‐Nuuk citizens reported improved social functioning compared with Nuuk citizens (p = .05). After 3 months, Global Health in Nuuk citizens was improved compared with non‐Nuuk citizens (p = .05). An important clinical finding was that patients’ needs for support are related to social status, and geographical factors should be taken into account when planning palliative care.     

Zur cellulären immunität beim melanomalignom

Zusammenfassung Es wurden 20 Patienten mit Melanomalignomen in verschiedenen klinischen Stadien mit Hilfe des Leukocyten-Migrations-Inhibitions-Testes auf das Vorliegen einer cellulären immunologischen Reaktivität untersucht. Als Antigene wurden drei homologe Melanomextrakte verwendet, die nach eigener Methode hergestellt wurden. Bei 15 von den 20 Probanden konnte — unabhängig vom klinischen Stadium — eine Hemmung der Zellmigration festgestellt werden. Damit ist erwiesen, daß die verwendeten Tumorextrakte Melanom-assoziierte Antigene enthalten. Der Träger eines MM entwickelt gegen diese Tumorantigene eine celluläre Immunität unabhängig vom klinischen Stadium des Tumorleidens. Auffallend ist, daß der tatsächliche Krankheitsablauf durch Immunmechanismen wenig beeinflußt zu sein scheint. Trotzdem dürfte eine weitere Beschäftigung mit dem Problem der Immuntherapie des Melanomalignoms gerechtfertigt und angezeigt sein.

---

Cellular immunity in melanomalignome

Summary Cellular immunological reactivity was examined in 20 patients having melanomalignoma at different clinical stages, using the Leukocyte-Migration-Inhibition-Test. As antigens three homologous melanoma-extracts were used, produced by our own method. Independent from the clinical stages cell-migration inhibition could be established in 15 out of the 20 patients. In this way, these tumor extracts have been shown to contain melanoma-associated antigens. Regardless of the clinical stage of the disease, the melanomalignomas patient produces cellular immunity against those tumor-antigens. It is note-worthy that the actual course of the disease seems not to be influenced by immun-mechanisms.

---

---

Auszugsweise vorgetragen (Fritz) bei der Tagung der Ungarischen Dermatologischen Gesellschaft in Szeged vom 17. – 18. 10. 1975.